Table 1.
Demographic and clinical parameters in the cerebrospinal fluid and serum in the cohort of patients with PD and control participants.
| Parameters | PD (n = 34) | Control (n = 30) | p |
|---|---|---|---|
| Age, years | 65 ± 12 | 57.4 ± 14 | NS |
| Gender, male n(%) | 18 (60) | 13(45) | NS |
| Body mass index, kg/m2 | 23.2 ± 3 | 24.6 ± 3 | NS |
| Education, years | 17.3 ± 1.6 | 17.4 ± 3.5 | NS |
| Albumin index | 6.9 ± 1.9 | 6.6 ± 1.6 | NS |
| Leukocyte count, cells/µL | 3.1 ± 0.7 | 2.7 ± 0.6 | NS |
| CSF MPO content, pg/mL | 114 ± 73 | 101 ± 43 | NS |
| CSF MPO activity, mU/mL | 0.0290 ± 0.001 | 0.0292 ± 0.001 | NS |
| Serum MPO content, pg/mL | 3770 ± 2871 | 1430 ± 683 | <0.0001 |
| Serum MPO activity, mU/mL | 44.1 ± 6 | 35.1 ± 7 | <0.0001 |
| CSF AOPP content, µM | 23.4 ± 29 (n = 16) | nd | |
| Serum AOPP content, µM | 535 ± 349 | nd | |
| Levodopa equivalent daily dose, mg | 686.2 ± 532 | ||
| Disease duration, years | 12.1 ± 7.8 | ||
| Age at PD onset, years | 51.2 ± 14 | ||
| Modified Hoehn–Yahr stage | 2.1 ± 0.7 | ||
| Modified Schwab–England | 77.8 ± 24 | ||
| MDS-UPDRS part III (on) | 25.6 ± 15 | ||
| Total MDS-UPDRS (I-III) (on) | 37.9 ± 26 | ||
| MDS-UPDRS part IV (all patients) | 1.2 ± 2.2 |
Mean ± SD. Statistical comparisons were carried out with the χ2 test (dichotomous variables) or the Student’s t-test (quantitative variables). Abbrev.: AOPP, advanced oxidation protein products; CSF, cerebrospinal fluid; MDS-UPDRS, International Parkinson and Movement Disorder Society-Sponsored revision of the Unified Parkinson’s Disease Rating Scale; MPO, myeloperoxidase; nd, non-detectable; NS, not significant; p, two-tailed probability value; PD, Parkinson’s disease.